Should androgen supplementation be used for poor ovarian response in IVF?

Sesh Kamal Sunkara, Arri Coomarasamy, Wiebke Arlt, Siladitya Bhattacharya

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Poor ovarian response is reported in 9–24% of IVF cycles. Several interventions have been proposed to improve the outcome, although evidence to support these has been scant. There has been interest in the use of adjuvant androgens in this context and a recent worldwide survey showed that nearly a quarter of IVF clinicians used dehydroepiandrosterone (DHEA) in poor responders. We examine the rationale for the use of adjuvant androgens and suggest that the current clinical uncertainty should be addressed by a randomized controlled trial of DHEA in poor responders.
Original languageEnglish
Pages (from-to)637-640
Number of pages4
JournalHuman Reproduction
Volume27
Issue number3
Early online date16 Jan 2012
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Dehydroepiandrosterone
Androgens
Uncertainty
Randomized Controlled Trials
Surveys and Questionnaires

Keywords

  • poor ovarian response
  • androgens
  • IVF treatment

Cite this

Should androgen supplementation be used for poor ovarian response in IVF? / Sunkara, Sesh Kamal; Coomarasamy, Arri ; Arlt, Wiebke; Bhattacharya, Siladitya.

In: Human Reproduction, Vol. 27, No. 3, 03.2012, p. 637-640.

Research output: Contribution to journalArticle

Sunkara, Sesh Kamal ; Coomarasamy, Arri ; Arlt, Wiebke ; Bhattacharya, Siladitya. / Should androgen supplementation be used for poor ovarian response in IVF?. In: Human Reproduction. 2012 ; Vol. 27, No. 3. pp. 637-640.
@article{530a431379e4421ead98d3f41da813da,
title = "Should androgen supplementation be used for poor ovarian response in IVF?",
abstract = "Poor ovarian response is reported in 9–24{\%} of IVF cycles. Several interventions have been proposed to improve the outcome, although evidence to support these has been scant. There has been interest in the use of adjuvant androgens in this context and a recent worldwide survey showed that nearly a quarter of IVF clinicians used dehydroepiandrosterone (DHEA) in poor responders. We examine the rationale for the use of adjuvant androgens and suggest that the current clinical uncertainty should be addressed by a randomized controlled trial of DHEA in poor responders.",
keywords = "poor ovarian response, androgens, IVF treatment",
author = "Sunkara, {Sesh Kamal} and Arri Coomarasamy and Wiebke Arlt and Siladitya Bhattacharya",
year = "2012",
month = "3",
doi = "10.193/humrep/der464",
language = "English",
volume = "27",
pages = "637--640",
journal = "Human Reproduction",
issn = "0268-1161",
publisher = "OXFORD UNIV PRESS",
number = "3",

}

TY - JOUR

T1 - Should androgen supplementation be used for poor ovarian response in IVF?

AU - Sunkara, Sesh Kamal

AU - Coomarasamy, Arri

AU - Arlt, Wiebke

AU - Bhattacharya, Siladitya

PY - 2012/3

Y1 - 2012/3

N2 - Poor ovarian response is reported in 9–24% of IVF cycles. Several interventions have been proposed to improve the outcome, although evidence to support these has been scant. There has been interest in the use of adjuvant androgens in this context and a recent worldwide survey showed that nearly a quarter of IVF clinicians used dehydroepiandrosterone (DHEA) in poor responders. We examine the rationale for the use of adjuvant androgens and suggest that the current clinical uncertainty should be addressed by a randomized controlled trial of DHEA in poor responders.

AB - Poor ovarian response is reported in 9–24% of IVF cycles. Several interventions have been proposed to improve the outcome, although evidence to support these has been scant. There has been interest in the use of adjuvant androgens in this context and a recent worldwide survey showed that nearly a quarter of IVF clinicians used dehydroepiandrosterone (DHEA) in poor responders. We examine the rationale for the use of adjuvant androgens and suggest that the current clinical uncertainty should be addressed by a randomized controlled trial of DHEA in poor responders.

KW - poor ovarian response

KW - androgens

KW - IVF treatment

U2 - 10.193/humrep/der464

DO - 10.193/humrep/der464

M3 - Article

VL - 27

SP - 637

EP - 640

JO - Human Reproduction

JF - Human Reproduction

SN - 0268-1161

IS - 3

ER -